Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 316 to 330 of 1346 results for long term conditions

  1. Domestic violence and abuse: multi-agency working (PH50)

    This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.

  2. Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula (HTG777)

    Evidence-based recommendations on transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula. This involves inserting a catheter through the femoral vein and injecting embolisation liquid to seal the fistula.

  3. Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome (HTG623)

    Evidence-based recommendations on personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. This involves opening the chest through the breastbone and wrapping a mesh around the outside of the aorta at the part closest to the heart.

  4. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST22)

    Evidence-based recommendations on ataluren (Translarna) for Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk.

  5. Prostatitis (acute): antimicrobial prescribing (NG110)

    This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.

  6. Golimumab for treating active non-radiographic axial spondyloarthritis (TA497)

    Evidence-based recommendations on golimumab (Simponi) for treating active non-radiographic axial spondyloarthritis.

  7. Fetoscopic prenatal repair for open neural tube defects in the fetus (HTG536)

    Evidence-based recommendations on fetoscopic prenatal repair of open neural tube defects in the fetus. This involves keyhole surgery through the woman’s abdomen to close the gap in the baby’s spine.

  8. Regorafenib for previously treated metastatic colorectal cancer (TA866)

    Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.

  9. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over (TA1033)

    Evidence-based recommendations on ganaxolone (Ztalmy) for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over.

  10. Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

    Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.

  11. Kidney conditions: CKD and SGLT2 inhibitors (IND324)

    This indicator covers the percentage of patients on the CKD register who are treated with an SGLT-2 inhibitor if they have: type 2 diabetes, or no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2 and are currently treated with an ACE inhibitor or angiotensin receptor blocker (ARB) (unless these are contraindicated) or an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2, are currently treated with an ACE inhibitor or ARB (unless these are contraindicated) and have a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.

  12. Rheumatoid arthritis: register (IND107)

    This indicator covers producing a register of all patients aged 16 years and over with rheumatoid arthritis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM55

  13. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090)

    Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.

  14. Gambling-related harms: identification, assessment and management (NG248)

    This guideline covers identifying, assessing and treating gambling-related harms. This includes people aged 18 and over who are experiencing gambling that harms, and people of any age affected by someone close to them who is experiencing gambling that harms.

  15. Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people (HTG684)

    Evidence-based recommendations on minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people. This involves inserting a rod along the spine through a small cut in the back.